24.6 %Pretreatment HIV drug resistance (PDR) frequency was 24.6% in Togo.
TogoVIH/sidapublished 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument of 9 observationsDOI 10.1093/jac/dky443
Explore evidence
Gold tier: mechanically validated evidence, with its primary source.
6 evidence items · page 1 / 1
0 %HLA-B*57:01 prevalence was 0.0% in Togo among individuals with HIV-1.
TogoVIH/sidaobserved 2016–2020published 2021BMC immunologyeurope_pmcdocument of 4 observationsDOI 10.1186/s12865-021-00427-7
69.8 %A total of 4016 individuals with HIV were enrolled, of whom 69.8% were women.
TogoVIH/sidaobserved 2016–2020published 2021BMC immunologyeurope_pmcdocument of 4 observationsDOI 10.1186/s12865-021-00427-7
45 yearsThe median age of enrolled individuals with HIV was 45 years, with an interquartile range of 38–52 years.
TogoVIH/sidaobserved 2016–2020published 2021BMC immunologyeurope_pmcdocument of 4 observationsDOI 10.1186/s12865-021-00427-7
2.3 %The HIV prevalence rate is 2.3% in Togo.
TogoVIH/sidaHAL · Unilimdocument of 97 observations
0.1 %The overall HLA-B*57:01 prevalence was 0.1% among individuals with HIV-1 in West and Central Africa.
TogoVIH/sidaobserved 2016–2020published 2021BMC immunologyeurope_pmcdocument of 4 observationsDOI 10.1186/s12865-021-00427-7
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.